Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
Avidity Biosciences Price Target Cut to $53.00/Share From $54.00 by Evercore ISI Group
Avidity Biosciences Analyst Ratings
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $53
Evercore Maintains Avidity Biosciences(RNA.US) With Buy Rating, Cuts Target Price to $53
Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating
BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating With New Price Objective
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
Leerink Partners Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $64
Avidity Biosciences Analyst Ratings
Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54
Avidity Biosciences (RNA) Gets a Buy From Evercore ISI
Avidity Biosciences Receives Buy Rating on Strong Clinical Results and Strategic Growth Prospects
Avidity Biosciences Earns Buy Rating on Strong Clinical Trial Results for Duchenne Muscular Dystrophy Treatment
Cantor Fitzgerald Keeps Their Buy Rating on Avidity Biosciences (RNA)